Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

Empirical Bayes (“post hoc”) estimates (EBEs) of ηs provide modelers with diagnostics: the EBEs themselves, individual prediction (IPRED), and residual errors (individual weighted residual (IWRES)). When data are uninformative at the individual level, the EBE distribution will shrink towards zero (η-shrinkage, quantified as 1-SD(ηEBE)/ω), IPREDs towards the corresponding observations, and IWRES towards zero (ε-shrinkage, quantified as 1-SD(IWRES)). These diagnostics are widely used in pharmacokinetic (PK) pharmacodynamic (PD) modeling; we investigate here their usefulness in the presence of shrinkage. Datasets were simulated from a range of PK PD models, EBEs estimated in non-linear mixed effects modeling based on the true or a misspecified model, and desired diagnostics evaluated both qualitatively and quantitatively. Identified consequences of η-shrinkage on EBE-based model diagnostics include non-normal and/or asymmetric distribution of EBEs with their mean values (“ETABAR”) significantly different from zero, even for a correctly specified model; EBE–EBE correlations and covariate relationships may be masked, falsely induced, or the shape of the true relationship distorted. Consequences of ε-shrinkage included low power of IPRED and IWRES to diagnose structural and residual error model misspecification, respectively. EBE-based diagnostics should be interpreted with caution whenever substantial η- or ε-shrinkage exists (usually greater than 20% to 30%). Reporting the magnitude of η- and ε-shrinkage will facilitate the informed use and interpretation of EBE-based diagnostics.

[1]  L B Sheiner,et al.  Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.

[2]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[3]  L Aarons,et al.  Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.

[4]  Marie Davidian,et al.  Nonlinear Models for Repeated Measurement Data , 1995 .

[5]  M O Karlsson,et al.  Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. , 1997, British journal of clinical pharmacology.

[6]  M O Karlsson,et al.  Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone , 1998, Clinical pharmacology and therapeutics.

[7]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[8]  G. Molenberghs,et al.  Linear Mixed Models for Longitudinal Data , 2001 .

[9]  M O Karlsson,et al.  Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. , 2001, British journal of clinical pharmacology.

[10]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mats O Karlsson,et al.  Population pharmacokinetics of levosimendan in patients with congestive heart failure. , 2003, British journal of clinical pharmacology.

[12]  Staffan Eriksson,et al.  Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. , 2003, Haematologica.

[13]  Mats O. Karlsson,et al.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial , 2003, European Journal of Clinical Pharmacology.

[14]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.

[15]  Mats O. Karlsson,et al.  Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  Mats O. Karlsson,et al.  Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.

[17]  Ene I. Ette,et al.  Population Pharmacokinetic Modeling: The Importance of Informative Graphics , 1995, Pharmaceutical Research.

[18]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  Mats O Karlsson,et al.  Pharmacokinetics of Ximelagatran and Relationship to Clinical Response in Acute Deep Vein Thrombosis , 2005, Clinical pharmacology and therapeutics.

[20]  Mats O Karlsson,et al.  Application of population pharmacokinetics to cladribine , 2005, BMC pharmacology.

[21]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  Alain Durand,et al.  Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  Manuel Hidalgo,et al.  CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. , 2006, Journal of the National Cancer Institute.

[25]  Grant Langdon,et al.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients , 2006, European Journal of Clinical Pharmacology.

[26]  R. Savic,et al.  Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults , 2006, Journal of clinical pharmacology.

[27]  Andrew C. Hooker,et al.  Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method , 2007, Pharmaceutical Research.

[28]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[29]  Yaning Wang Derivation of various NONMEM estimation methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  Ene I. Ette,et al.  Pharmacometrics : the science of quantitative pharmacology , 2007 .

[31]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  Comprar Pharmacometrics: The Science of Quantitative Pharmacology | Paul J. Williams | 9780471677833 | Wiley , 2007 .

[33]  Yaning Wang,et al.  Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications , 2005, The AAPS Journal.

[34]  Janet R. Wade,et al.  A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective , 2005, The AAPS Journal.

[35]  Mats O Karlsson,et al.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. , 2008, British journal of clinical pharmacology.

[36]  E. Björk,et al.  Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment , 2008, Clinical pharmacology and therapeutics.

[37]  Mats O. Karlsson,et al.  Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.

[38]  Mats O Karlsson,et al.  Evaluation of the nonparametric estimation method in NONMEM VI. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.